A strategy for assessing potential drug-drug interactions of a concomitant agent against a drug absorbed via an intestinal transporter in humans

Drug Metabolism and Disposition

Volumn 42, Issue 9, 2014, Pages 1456-1465

  Mizuno Yasuhira, Akiko ^a   Nakai, Yasuhiro ^b   Gunji, Emi ^b   Uchida, Saeko ^b   Takahashi, Teisuke ^b   Kinoshita, Kohnosuke ^a   Jingu, Shigeji ^a   Sakai, Soichi ^b   Samukawa, Yoshishige ^b   Yamaguchi, Jun Ichi ^a  

^a Departments of Drug Safety and Pharmacokinetics Laboratories   (Japan)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXYNOJIRIMYCIN; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; CARRIER PROTEIN; MIGLITOL; SODIUM GLUCOSE COTRANSPORTER 1; SORBITOL;

ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; CELL LINE; CHO CELL LINE; COMPUTER SIMULATION; CRICETULUS; DRUG INTERACTION; HUMAN; INTESTINE; INTESTINE ABSORPTION; MALE; METABOLISM; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

1-DEOXYNOJIRIMYCIN; ANIMALS; CELL LINE; CHO CELLS; COMPUTER SIMULATION; CRICETULUS; DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; MALE; MEMBRANE TRANSPORT PROTEINS; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-GLUCOSE TRANSPORTER 1; SORBITOL;

EID: 84906887747     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.058305     Document Type: Article

References (28)

1. Agoram B, Woltosz WS, and Bolger MB (2001) Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50 (Suppl 1):S41-S67. (Pubitemid 32905355)
2. Amidon GL, Lennernäs H, Shah VP, and Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
3. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, and Feder JN (2010) Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 1:57-92.
4. 50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm 7:398-411.
5. Fagerholm U, Johansson M, and Lennernäs H (1996) Comparison between permeability coefficients in rat and human jejunum. Pharm Res 13:1336-1342. (Pubitemid 26344978)
6. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, and Hyland R, et al. (2009) Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658-1666.
7. Hediger MA and Rhoads DB (1994) Molecular physiology of sodium-glucose cotransporters. Physiol Rev 74:993-1026. (Pubitemid 24328943)
8. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, and Webster R, et al. (2009) Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513-533.
9. Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, and Wright EM (2011) Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 300:C14-C21.
10. Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, Arai M, Kawakita Y, Fukasawa Y, Iida I, Hagima N, Takeuchi H, and Chino Y, et al. (2010) (1S)-1,5-anhydro-1-[5- (4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 53:3247-3261.
11. Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T, and Sugiyama Y (2008) The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm Res 25:1891-1901.
12. Khan A and Efendic S (1995) Evidence that increased glucose cycling in islets of diabetic ob/ob mice is a primary feature of the disease. Am J Physiol 269:E623-E626.
13. Komiya I, Park JY, Kamani A, Ho NFH, and Higuchi WI (1980) Quantitative mechanistic studies in simultaneous fluid flow and intestinal absorption using steroids as model solutes. Int J Pharm 4:249-262. (Pubitemid 10114888)
14. Krook A, Kawano Y, Song XM, EfendiS, Roth RA, Wallberg-Henriksson H, and Zierath JR (1997) Improved glucose tolerance restores insulin-stimulated Akt kinase activity and glucose transport in skeletal muscle from diabetic Goto-Kakizaki rats. Diabetes 46:2110-2114. (Pubitemid 27512106)
15. Kuboyama N, Hayashi I, and Yamaguchi T (2006) [Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor]. Nippon Yakurigaku Zasshi 127:223-232.
16. +/glucose cotransporter. Re-evaluation of function and distribution of expression. J Biol Chem 269:12032-12039.
17. Mizuno-Yasuhira A, Kinoshita K, Jingu S, and Yamaguchi JI (2014) A sensitive and selective method for the quantitative analysis of miglitol in rat plasma using unique solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr DOI: 10.1002/bmc.3185 [published ahead of print].
18. Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, and Rostami-Hodjegan A (2013) Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin. J Pharm Sci 102:3161-3173.
19. Pérez López G, González Albarrán O, and Cano Megías M (2010) [Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus]. (in Spanish) Nefrologia 30:618-625.
20. Reyner EL, Sevidal S, West MA, Clouser-Roche A, Freiwald S, Fenner K, Ullah M, Lee CA, and Smith BJ (2013) In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions. Drug Metab Dispos 41:1575-1583.
21. Sels JPJE, Huijberts MSP, and Wolffenbuttel BHR (1999) Miglitol, a new α-glucosidase inhibitor. Expert Opin Pharmacother 1:149-156.
22. Shugarts S and Benet LZ (2009) The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 26:2039-2054.
23. Suzuki M, Honda K, Fukazawa M, Ozawa K, Hagita H, Kawai T, Takeda M, Yata T, Kawai M, and Fukuzawa T, et al. (2012) Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 341:692-701.
24. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, and Tomiyama H, et al. (2012) Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 385:423-436.
25. Washburn WN and Poucher SM (2013) Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 22:463-486.
26. Yamaoka K, Nakagawa T, and Uno T (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175. (Pubitemid 8384279)
27. Yu LX, Lipka E, Crison JR, and Amidon GL (1996) Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev 19:359-376. (Pubitemid 26227526)
28. Zhang W, Krauwinkel WJJ, Keirns J, Townsend RW, Lasseter KC, Plumb L, Kadokura T, Ushigome F, and Smulders R (2013) The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor. Clin Drug Investig 33:489-496.